Table 2:
Distribution of treated hypertensive participants by antihypertensive drug use as monotherapy, or as a specific combination (two, three or more) and associated control rates. Note, percentages are reported as a total of all antihypertensive regimens utilized in the cohort.
| Medication | Australia (N=8748) | US (N=1314) | P-valuea | |||
|---|---|---|---|---|---|---|
| % usage (n) | % Controlled (95% CI) | % usage (n) | % Controlled (95% CI) | usage | control | |
| Monotherapy | ||||||
| RAS | 35.9 (3139) | 45.5 (43.7–47.2) | 20.9 (275) | 54.2 (48.3–60.1) | <0.001 | 0.002 |
| DU | 3.8 (332) | 45.2 (39.8–50.5) | 9.4 (124) | 64.5 (56.1–72.9) | <0.001 | 0.001 |
| CCB | 6.1 (533) | 34.9(30.8–38.9) | 7.5 (98) | 57.1 (47.3–66.9) | 0.292 | 0.107 |
| BB | 3.4 (295) | 46.8 (41.1–52.3) | 5.7 (75) | 52.0 (40.7–63.3) | <0.001 | 0.057 |
| Other mono therapy | 1.6 (136) | 44.1 (35.8–52.5) | 0.9 (12) | 50.0 (21.7–78.3) | 0.369 | 0.169 |
| Two drug combination | ||||||
| RAS+ DU | 15.6 (1368) | 50.2 (47.5–52.8) | 13.9 (183) | 65.6 (58.7–72.5) | 0.131 | 0.001 |
| RAS+CCB | 12.3 (1072) | 46.2 (43.2–49.2) | 7.3 (96) | 49.0 (39.0–59.0) | 0.004 | 0.514 |
| RAS+BB | 2.8 (242) | 40.9 (34.7–47.1) | 3.2 (42) | 52.4 (37.3–67.5) | 0.102 | 0.069 |
| DU +BB | 0.7 (60) | 50.0 (37.3–62.7) | 4.6 (60) | 65.0 (52.9–77.1) | <0.001 | 0.338 |
| Other 2 combinations | 3.4 (297) | 42.8 (37.1–48.4) | 7.5 (99) | 54.6 (44.7–64.4) | <0.001 | 0.379 |
| Three or more drug combination | ||||||
| RAS +DU +CCB | 6.9 (601) | 45.3 (41.3–49.2) | 6.0 (79) | 58.2 (47.4–69.1) | 0.023 | 0.52 |
| RAS+ DU +BB | 1.8 (156) | 49.4 (41.5–57.2) | 4.3 (57) | 59.7 (46.9–72.4) | <0.001 | 0.966 |
| Other ≥3 combinations | 5.9 (517) | 45.5 (41.2–49.7) | 8.7 (114) | 50.0 (40.8–59.2) | 0.375 | 0.144 |
Abbreviations: RAS = renin-angiotensin blocking drug, DU = diuretic, CCB = calcium channel blocker, BB = beta blocker
a
P-value for comparison between U.S. and Australian participants adjusted for age, sex, BMI, and race